GW Pharma (GWPH) Announces 1.7M ADS Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
GW Pharma (GWPH) Prices 1.7M Offering at $86.83/ADS
June 19, 2014 7:36 AM EDTGW Pharma (NASDAQ: GWPH) the pricing of an underwritten public offering by the Company and certain of its shareholders of 1,700,000 American Depositary Shares ("ADSs") representing 20,400,000 ordinary shares of GW, at a price to the public of $86.83 per ADS on the NASDAQ Global... More
GW Pharma (GWPH) Updates on Physician Reports from 12-Week Epidiolex Treatment Regime
June 17, 2014 7:06 AM EDTGW Pharmaceuticals plc (Nasdaq: GWPH) announced physician reports of efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with GW's investigational cannabidiol (CBD) product candidate, Epidiolex®, for a period of 12 weeks. The treatment-resistant patients suffer from a range of epilepsies in which current anti-epileptic drugs have been unsuccessful in adequately controlling seizures, and included such severe forms of epilepsy as Dravet syndrome and Lennox-Gastaut syndrome. Uncontrolled data from two hospital sites in the United States that were generated under expanded access Investigational New Drug applications (INDs)... More
